Princeton, NJ (September 27, 2004) – In type 2 diabetes patients, use of NovoLog® Mix 70/30 FlexPen® (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback